Evaluating novel COVID-19 vaccines in the current chapter of the pandemic

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	1652-1654
Number of pages	3
Journal	The Lancet Infectious Diseases
Volume	22
Issue number	12
DOIs	https://doi.org/10.1016/S1473-3099(22)00517-5
Publication status	E-pub ahead of print - 5 Sep 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{04bb508973494116b4f485cfbb12c70a,

title = "Evaluating novel COVID-19 vaccines in the current chapter of the pandemic",

author = "GeurtsvanKessel, {Corine H} and {de Vries}, {Rory D}",

year = "2022",

month = sep,

day = "5",

doi = "10.1016/S1473-3099(22)00517-5",

language = "English",

volume = "22",

pages = "1652--1654",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Lancet Publishing Group",

number = "12",

}

TY - JOUR

T1 - Evaluating novel COVID-19 vaccines in the current chapter of the pandemic

AU - GeurtsvanKessel, Corine H

AU - de Vries, Rory D

PY - 2022/9/5

Y1 - 2022/9/5

U2 - 10.1016/S1473-3099(22)00517-5

DO - 10.1016/S1473-3099(22)00517-5

M3 - Comment/Letter to the editor

C2 - 36075232

VL - 22

SP - 1652

EP - 1654

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 12

ER -